Page 135 - 2021_03-Haematologica-web

HLA-G corrects dysfunction of immune cells in ITP
16. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J. 2005;19(7):681-693.
17. Wang Q, Song H, Cheng H, et al. Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cell Mol Immunol. 2020;17(9):966-975.
18. Kirszenbaum M, Moreau P, Gluckman E, Dausset J, Carosella E. An alternatively spliced form of HLA-G mRNA in human tro- phoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci U S A. 1994;91(10):4209-4213.
19. Le Friec G, Gros F, Sebti Y, et al. Capacity of myeloid and plasmacytoid dendritic cells especially at mature stage to express and secrete HLA-G molecules. J Leukoc Biol. 2004;76(6):1125-1133.
20. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells sup- presses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A. 2001;98(21):12150- 12155.
21. Naji A, Menier C, Morandi F, et al. Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol. 2014;192(4):1536-1546.
22. Zarkhin V, Talisetti A, Li L, et al. Expression of soluble HLA-G identifies favorable out- comes in liver transplant recipients. Transplantation. 2010;90(9):1000-1005.
23. Le Rond S, Azema C, Krawice-Radanne I, et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol. 2006;176(5):3266-3276.
24. Qiu J, Terasaki PI, Miller J, Mizutani K, Cai J, Carosella ED. Soluble HLA-G expression and renal graft acceptance. Am J Transplant. 2006;6(9):2152-2156.
25. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005; 65(22):10139-10144.
26. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is asso- ciated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105(4):1694-1698.
27. Verbruggen LA, Rebmann V, Demanet C, De Cock S, Grosse-Wilde H. Soluble HLA-G in rheumatoid arthritis. Hum Immunol. 2006;67(8):561-567.
28. Mitsdoerffer M, Schreiner B, Kieseier BC, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon- beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol. 2005;159(1-2):155-164.
29. Chen J, Shen B, Jiang Y, et al. Analysis of immunoglobulin-like transcripts (ILTs) in lymphocytes with sHLA-G and IL10 from SLE patients. Clin Exp Med. 2013;13(2):135- 142.
30. Guerra-de Blas Pdel C, Villasenor-Talavera YS, Cruz-Gonzalez Dde J, et al. Analysis of
the expression and function of immunoglob- ulin-like transcript 4 (ILT4, LILRB2) in den- dritic cells from patients with systemic lupus erythematosus. J Immunol Res. 2016; 2016:4163094.
31. Kim SK, Jeong KH, Kang IJ, Chung JH, Shin MK, Lee MH. Relationship between the HLA-G 14 bp insertion/deletion polymor- phism and susceptibility to autoimmune disease: a meta-analysis. Genet Mol Res. 2015;14(4):15839-15847.
32. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen present- ing cells, NK cells, and T cells. FASEB J. 2005;19(6):662-664.
33. LeMaoult J, Daouya M, Wu J, Loustau M, Horuzsko A, Carosella ED. Synthetic HLA- G proteins for therapeutic use in transplan- tation. FASEB J. 2013;27(9):3643-3651.
34. Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloim- mune thrombocytopenia: response to intra- venous IgG therapy. Blood. 2006; 107(7):2976-2983.
35. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell- mediated responses that are differentially sensitive to therapy. Blood. 2010; 115(6): 1247-1253.
36. Shiroishi M, Tsumoto K, Amano K, et al. Human inhibitory receptors Ig-like tran- script 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferen- tially to HLA-G. Proc Natl Acad Sci U S A. 2003;100(15):8856-8861.
37.Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol. 2000;164(12):6100-6104. LiS,WangL,ZhaoC,LiL,PengJ,HouM. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol. 2007;139(4):605-611.
39.ZhangJ,MaD,ZhuX,QuX,JiC,HouM. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica. 2009;94(9):1326- 1329.
40. Rocha AM, Souza C, Rocha GA, et al. The serum levels of the cytokines involved in the Th17 and Th1 cell commitment are increased in individuals with borderline thrombocytopenia. J Hematol Oncol. 2013;6:28.
41. Liu F, Wu C, Yang X, et al. Polarization and apoptosis of T cell subsets in idiopathic thrombocytopenic purpura. Cell Mol Immunol. 2005;2(5):387-392.
42. Agaugue S, Carosella ED, Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood. 2011;117(26):7021- 7031.
43. Feger U, Tolosa E, Huang YH, et al. HLA-G expression defines a novel regulatory T-cell
subset present in human peripheral blood and sites of inflammation. Blood. 2007; 110(2):568-577.
44. Huang YH, Zozulya AL, Weidenfeller C, Schwab N, Wiendl H. T cell suppression by naturally occurring HLA-G-expressing regu- latory CD4+ T cells is IL-10-dependent and reversible. J Leukoc Biol. 2009;86(2):273-281.
45. Pankratz S, Bittner S, Herrmann AM, et al. Human CD4+ HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo. FASEB J. 2014;28(8):3435- 3445.
46. Bayne LJ, Beatty GL, Jhala N, et al. Tumor- derived granulocyte-macrophage colony- stimulating factor regulates myeloid inflam- mation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21(6):822-835.
47. Pickup MW, Owens P, Gorska AE, et al. Development of aggressive pancreatic duc- tal adenocarcinomas depends on granulo- cyte colony stimulating factor secretion in carcinoma cells. Cancer Immunol Res. 2017; 5(9):718-729.
48.Moreau P, Flajollet S, Carosella ED. Non- classical transcriptional regulation of HLA- G: an update. J Cell Mol Med. 2009; 13(9B):2973-2989.
49. Ajith A, Portik-Dobos V, Nguyen-Lefebvre AT, et al. HLA-G dimer targets Granzyme B pathway to prolong human renal allograft survival. FASEB J. 2019;33(4):5220-5236.
50.Lesport E, Baudhuin J, LeMaoult J, et al. Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. Hum Immunol. 2009;70(12):1000-1005.
38.
51.
Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway. Proc Natl Acad Sci U S A. 2008; 105(24):8357-8362.
52.Le Friec G, Laupeze B, Fardel O, et al. Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum Immunol. 2003;64(8):752-761.
53. Kuroki K, Hirose K, Okabe Y, et al. The long- term immunosuppressive effects of disul- fide-linked HLA-G dimer in mice with colla- gen-induced arthritis. Hum Immunol. 2013; 74(4):433-438.
54. Akhter A, Faridi RM, Das V, Pandey A, Naik S, Agrawal S. In vitro up-regulation of HLA- G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage. Tissue Antigens. 2012;80(2):126-135.
55.Yan WH, Lin AF, Chang CC, Ferrone S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine. Cell Res. 2005;15(7):523-531.
56. Pedersen AE, Gad M, Walter MR, Claesson MH. Induction of regulatory dendritic cells by dexamethasone and 1alpha,25-dihydroxyvit- amin D(3). Immunol Lett. 2004;91(1):63-69.
haematologica | 2021; 106(3)
781